Key result
AI-driven MAESTRIA tool outperforms standard scores in predicting AF recurrence and stroke risk by ~0.15 AUC.
Why the study?
Early and personalized diagnosis of atrial cardiomyopathy to prevent atrial fibrillation requires integrating multiple imaging, electrocardiographic, biological, and genomic parameters.
Does an AI-driven multimodal clinical decision support tool improve the prediction of atrial fibrillation risk and diagnosis of atrial cardiomyopathy compared to standard clinical scores?
Does an AI-driven multimodal clinical decision support tool improve the prediction of atrial fibrillation risk and diagnosis of atrial cardiomyopathy compared to standard clinical scores?
An AI-driven multimodal decision support tool integrating clinical, imaging, and biological data improves the prediction of atrial fibrillation risk and diagnosis of atrial cardiomyopathy compared to standard clinical scores.
Answers are grounded in this paper and cite their sources.
Multi-modal integration may aid early atrial cardiomyopathy detection; hypothesis-generating and requires prospective validation before any clinical use.
Background Early and personalized diagnostic of the atrial cardiomyopathy that paves the way of atrial fibrillation (AF) is necessary for timely deployment of prevention strategies and personalised medical care. However, the diagnostic of the atrial cardiomyopathy needs to integrate multiple parameters including imaging, electrocardiographic, biological, genomic. Purpose To develop and validate an interoperable demonstrator integrating imaging, electrophysiology, clinical and omics data using explainable AI to support personalized diagnostic of the atrial cardiomyopathy and of the risk prediction of AF. Methods We harmonized multimodal datasets across several European centers, including clinical variables, ECG, echocardiography, cardiac-MRI, CT, wearable-datasets and omics. Predictive models were developed using ensemble machine learning algorithms (e.g., CatBoost, XGBoost), deep learning approaches for imaging segmentation, and multi-block data integration frameworks. Model interpretability was addressed through SHAP value analysis and partial dependence plots. The demonstrator was built as a GDPR-compliant, decision support tool with clinician-friendly interfaces. Results The demonstrator integrates validated models predicting AF recurrence, stroke risk, and atrial cardiomyopathy. By integrating ECG, echo, MRI, CT, and omics data, it significantly outperforms standard clinical scores, boosting prediction accuracy (AUC increase up to 0.15). External validation across multiple cohorts confirmed generalizability and clinical usability. Proof of concept studies have been conducted integrating echocardiography strain imaging, MRI imaging of the epicardial adipose tissue and biological parameters to predict the risk of AF recurrency and for early detection of the atrial cardiomyopathy. Conclusion The MAESTRIA Demonstrator, built on a robust multimodal AI framework, promises to be a powerful clinical tool enabling clinicians to predict, visualize, and interpret cardiovascular risk, particularly atrial fibrillation, through the integration of clinical, imaging, and biological data.
No takes yet. Share an insight, caveat, or question.
Ponnaiah et al. (2026) studied Atrial cardiomyopathy and atrial fibrillation. MAESTRIA Demonstrator (multimodal AI framework) vs. standard clinical scores was evaluated on Prediction accuracy (AUC) for AF recurrence, stroke risk, and atrial cardiomyopathy (AUC increase up to 0.15). The MAESTRIA Demonstrator, an AI-driven multimodal tool, outperformed standard clinical scores in predicting AF recurrence, stroke risk, and atrial cardiomyopathy (AUC increase up to 0.15).
Synapse has enriched 10 related papers. Consider them for comparative context: